IQVIA Holdings (IQV) AI Stock Analysis

• Market Cap: $37.75B
• Dividend Yield: N/A
• Average Volume (3M): 1.37M
• Price to Earnings (P/E): 30.4
• Beta (1Y): 0.83
• Revenue Growth: 3.85%
• EPS Growth: -4.74%
• Country: US
• Employees: 89,000
• Sector: N/A
• Sector Strength: N/A
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 3.00
• Shares Outstanding: 170,300,000
• 10 Day Avg. Volume: 1,507,926
• 30 Day Avg. Volume: 1,368,386
• PEG Ratio: 10.65
• Price to Book (P/B): 5.87
• Price to Sales (P/S): 2.31
• P/FCF Ratio: 16.85
• Enterprise Value/Market Cap: 1.22
• Enterprise Value/Revenue: 2.89
• Enterprise Value/Gross Profit: 8.56
• Enterprise Value/Ebitda: 13.38
• 1Y Price Target: $244.85
• Price Target Upside: 10.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15
• EPS Forecast (FY): 11.89
• Revenue Forecast (FY): $16.19B

• Rating: 73 Outperform
• Price Target: $243.00 ▲(9.74% Upside)

IQVIA Holdings scores well due to strong financial performance and positive earnings call sentiment, driven by robust revenue growth and strategic focus on AI. However, the high P/E ratio suggests potential overvaluation, and technical indicators reflect a neutral market sentiment. Recent corporate events further bolster the company's strategic positioning.

IQVIA Holdings Business Overview & Revenue Model

Company Description

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

How the Company Makes Money

IQVIA generates revenue through a diversified model that includes consulting services, technology solutions, and contract research services. The Technology & Analytics Solutions segment offers data analytics and software solutions that help clients make informed decisions in drug development and market access, which contributes significantly to its revenue. The Contract Research Services segment provides clinical trial management and related services, generating revenue through project-based contracts with pharmaceutical companies. Additionally, IQVIA has established strategic partnerships with healthcare organizations and technology companies, allowing it to expand its service offerings and access new markets. The company also benefits from a subscription-based revenue model for certain analytics services, contributing to recurring revenue streams.

IQVIA Holdings Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

IQVIA Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 221.43
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IQV, the sentiment is Neutral. The current price of 221.43 is below the 20-day moving average (MA) of 224.44, above the 50-day MA of 217.16, and above the 200-day MA of 181.66, indicating a neutral trend. The MACD of 1.74 indicates Positive momentum. The RSI at 50.19 is Neutral, neither overbought nor oversold. The STOCH value of 54.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IQV.

IQVIA Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
MEDP	79 Outperform	$15.74B	38.96	73.70%	―	13.88%	23.92%
DGX	79 Outperform	$19.87B	20.96	13.69%	1.76%	13.74%	14.87%
DHR	75 Outperform	$158.72B	46.25	6.84%	0.53%	2.22%	-7.60%
IQV	73 Outperform	$37.75B	30.40	19.55%	―	3.85%	-4.74%
TMO	72 Outperform	$214.21B	32.94	13.14%	0.30%	3.22%	8.26%
ICLR	68 Neutral	$13.93B	24.25	6.27%	―	-2.46%	-17.89%

IQVIA Holdings Corporate Events

IQVIA Holdings Amends Credit Agreement for Refinancing

On December 9, 2025, IQVIA Holdings Inc. amended its Fifth Amended and Restated Credit Agreement to refinance its term loans and revolving credit commitments into new classes, reduce interest rates on certain loans, and release specific subsidiaries from borrowing obligations. This strategic financial restructuring is likely to enhance IQVIA’s operational efficiency and financial flexibility, potentially strengthening its position in the healthcare analytics and research market.

IQVIA Holdings Appoints Nobel Laureate to Board

On November 5, 2025, IQVIA Holdings Inc. announced the appointment of Dr. William G. Kaelin Jr. to its Board of Directors. Dr. Kaelin, a Nobel Prize-winning scientist with extensive expertise in oncology and biomedical innovation, is expected to enhance the board’s capabilities. This strategic appointment is likely to strengthen IQVIA’s industry positioning by leveraging Dr. Kaelin’s scientific expertise and leadership experience, potentially benefiting stakeholders through advanced insights and innovation in healthcare solutions.